Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface
The association of Immunoscore and TB with patient survival suggests that both biomarkers are complementary and should be interpreted in combination to identify high-risk Stage I-II patients who should be considered for adjuvant therapy or further diagnostic testing.
Authors
- Tariq Haddad
- Francesco Ciompi
- Femke Simmer (ORCID: https://orcid.org/0000-0002-3020-1896)
- John‐Melle Bokhorst (ORCID: https://orcid.org/0000-0001-7231-8833)
- Irıs D. Nagtegaal (ORCID: https://orcid.org/0000-0003-0887-4127)
- Alessandro Lugli (ORCID: https://orcid.org/0000-0002-9264-5185)
- Martin D. Berger (ORCID: https://orcid.org/0000-0001-9224-7104)
- Jérôme Galon (ORCID: https://orcid.org/0000-0001-9635-1339)
- Inti Zlobec (ORCID: https://orcid.org/0000-0001-6741-3000)
- Jeroen van der Laak (ORCID: https://orcid.org/0000-0001-7982-0754)
- Franck Pagès (ORCID: https://orcid.org/0000-0002-2083-610X)
- Luuk van den Dobbelsteen
Institutions
- University of Bern (CH)
- Radboud University Nijmegen (NL)
- Université Paris Cité (FR)
- University Hospital of Bern (CH)
- Radboud University Medical Center (NL)
- Sorbonne Université (FR)
- Centre de Recherche des Cordeliers (FR)
- Radboud Institute for Molecular Life Sciences (NL)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-12-02
- DOI
- https://doi.org/10.1186/s12967-024-05818-z
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- KWF Kankerbestrijding
- Radboud Universitair Medisch Centrum